Dragonfly Therapeutics, Inc. added Robin Edwards and David Ferry to its clinical leadership team. Edwards will oversee translational medicine and Ferry will run clinical development in oncology. Edwards was previously global head of translational sciences at Daiichi Sankyo and head of translational pathology at Bristol Myers Squibb, while Ferry, was previously head of GI Oncology at Eli Lilly. “The encouraging clinical results we are seeing with our three internally owned drug progra...